亞洲 GLP-1 與肥胖藥
截至 2026 年 11 月 1 日，藥時事追蹤中國、日本、韓國與台灣的 GLP-1 與肥胖藥計畫，共 26 項；最高階段代表為 Chugai Pharmaceutical 的 orforglipron（已核准）。
資產 (26)
| 公司 | 國別 | 代號 | 資產 | 機制／格式 | 最高階段 | 適應症 | 合作夥伴與條件（首付／總額） | 來源 |
|---|---|---|---|---|---|---|---|---|
| Shanghai Benemae | 中國 | beinaglutide | beinaglutide | GLP-1R 胜肽 | 已核准 | 第二型糖尿病；體重管理 | — | benemae.com clinicaltrials.gov |
| Hanmi Pharmaceutical | 韓國 | efpeglenatide | efpeglenatide | GLP-1R 長效胜肽與 Fc 接合格式 | 已核准 | 肥胖（韓國） | — | www.hanmi.co.kr clinicaltrials.gov |
| 韓國 | efinopegdutide | efinopegdutide | GLP-1R × GCGR 雙重促效胜肽與 Fc 接合格式 | 二期 | 非酒精性脂肪肝病、非酒精性脂肪性肝炎、代謝功能障礙相關脂肪肝病及代謝功能障礙相關脂肪性肝炎 | Merck/MSD (ex-Korea) | clinicaltrials.gov | |
| 韓國 | HM15211 | efocipegtrutide | GLP-1R × GIPR × GCGR 三重促效胜肽與 Fc 接合格式 | 二期 | 非酒精性脂肪性肝炎 | — | clinicaltrials.gov | |
| 韓國 | HM15275 | — | GLP-1R × GIPR × GCGR 三重促效胜肽 | 二期 | 第二型糖尿病 | — | hanmipharm.com clinicaltrials.gov | |
| Hansoh Pharma | 中國 | loxenatide | polyethylene glycol loxenatide | GLP-1R PEG 化胜肽 | 已核准 | 第二型糖尿病 | — | www.hspharm.com clinicaltrials.gov |
| 中國 | HS-20094 | olatorepatide | GLP-1R × GIPR 雙重促效胜肽 | NDA 已送件 | 肥胖或過重成人的長期體重管理 | Regeneron USD 80m / USD 2010m | tc.hspharm.com clinicaltrials.gov www.hspharm.com | |
| Chugai Pharmaceutical | 日本 | orforglipron | orforglipron | GLP-1R 口服小分子 | 已核准 | 肥胖或過重 | Eli Lilly (global) | investor.lilly.com clinicaltrials.gov |
| PegBio | 中國 | PB-119 | visepegenatide | GLP-1R PEG 化胜肽 | 已核准 | 第二型糖尿病 | — | www.hkexnews.hk clinicaltrials.gov |
| Sciwind Biosciences | 中國 | XW003 | ecnoglutide | GLP-1R 胜肽 | 已核准 | 肥胖或過重者的長期體重管理；核准來源日期為 2026-03-06 | HK inno.N — / — | www.sciwindbio.com clinicaltrials.gov |
| 中國 | XW014 | — | GLP-1R 口服小分子 | 一期 | 第二型糖尿病 | — | sciwindbio.com clinicaltrials.gov | |
| BrightGene Bio-Medical | 中國 | BGM0504 | — | GLP-1R × GIPR 雙重促效胜肽 | NDA 已送件 | 肥胖或過重成人的長期體重管理 | — | www.bright-gene.com clinicaltrials.gov static.cninfo.com.cn |
| Hengrui Pharmaceuticals | 中國 | HRS-7535 | safiglipron (proposed INN) | GLP-1R 口服小分子 | NDA 已送件 | 第二型糖尿病；體重管理 | Hercules CM NewCo / Kailera（組合金額，未分攤） USD 100m / USD 6035m | www.kailera.com clinicaltrials.gov static.cninfo.com.cn |
| 中國 | HRS9531 | ribupatide | GLP-1R × GIPR 雙重促效胜肽 | NDA 已送件 | 肥胖或過重；第二型糖尿病 | Hercules CM NewCo / Kailera（組合金額，未分攤） USD 100m / USD 6035m | www.kailera.com clinicaltrials.gov static.cninfo.com.cn | |
| 中國 | HRS4729 | — | GLP-1R × GIPR × GCGR 三重促效胜肽 | 二期 | 代謝功能障礙相關脂肪性肝炎（MASH） | Kailera (ex-Greater China) | www.kailera.com clinicaltrials.gov | |
| CSPC Baike | 中國 | TG103 | 依达格鲁肽α (English INN 查無) | GLP-1R GLP-1 與 Fc 融合格式 | NDA 已送件 | 體重管理；第二型糖尿病 | — | clinicaltrials.gov www.e-cspc.com |
| Ascletis | 中國 | ASC30 | — | GLP-1R 小分子（口服及注射劑型） | 三期 | 肥胖、過重與長期體重管理 | — | www1.hkexnews.hk clinicaltrials.gov |
| Zhejiang Doer Biologics | 中國 | DR10624 | — | GLP-1R × GCGR × FGF21R 三重促效融合蛋白 | 三期 | 重度高三酸甘油脂血症 | — | en.huadongmedicine.com clinicaltrials.gov static.cninfo.com.cn |
| Eccogene | 中國 | ECC5004 | elecoglipron | GLP-1R 口服小分子 | 三期 | 肥胖或過重 | AstraZeneca USD 185m / USD 2010m | www.prnewswire.com clinicaltrials.gov |
| Gan & Lee Pharmaceuticals | 中國 | GZR18 | bofanglutide | GLP-1R 胜肽 | 三期 | 過重或肥胖 | Productos Cientificos / CARNOT Laboratorios — / — Lupin — / — JW Pharmaceutical USD 5m / USD 81.1m Menarini EUR 62m / EUR 726m | static.cninfo.com.cn clinicaltrials.gov |
| Hangzhou Zhongmei Huadong Pharmaceutical | 中國 | HDM1002 | conveglipron | GLP-1R 口服小分子 | 三期 | 第二型糖尿病 | — | en.huadongmedicine.com clinicaltrials.gov |
| 中國 | HDM1005 | poterepatide | GLP-1R × GIPR 雙重促效胜肽 | 三期 | 肥胖與過重 | — | disc.static.szse.cn clinicaltrials.gov | |
| MindRank | 中國 | MDR-001 | — | GLP-1R 口服小分子 | 三期 | 肥胖或過重 | — | www.mindrank.ai clinicaltrials.gov |
| The United Bio-Technology (Hengqin) | 中國 | UBT251 | — | GLP-1R × GIPR × GCGR 三重促效胜肽 | 三期 | 第二型糖尿病 | Novo Nordisk USD 200m / USD 2000m | www.novonordisk.com clinicaltrials.gov |
| D&D Pharmatech | 韓國 | DD01 | zabopegdutide | GLP-1R × GCGR 雙重促效胜肽 | 二期 | 非酒精性脂肪肝病；非酒精性脂肪性肝炎 | Salubris (China) | ddpharmatech.com clinicaltrials.gov |
| Dong-A ST | 韓國 | DA-1726 | — | GLP-1R × GCGR 雙重促效胜肽 | 一期 | 肥胖 | NeuroBo (global ex-selected Asia territories) | www.donga.co.kr clinicaltrials.gov |
亞洲對外授權 (15)
| 日期 | 授權方 | 國別 | 合作方 | 資產／組合 | 交易類型 | 地區 | 首付 | 潛在總額 | 條件 | 來源 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04 | D&D Pharmatech | South Korea | Metsera | DD02S / MET-002o; DD03 / MET-GGGo | PORTFOLIO_LICENSE | Global | — | USD 422.5m | Company timeline provides April 2023 and USD422.5m package total; no numerical upfront split. Later expansion is incremental, not a second copy of cumulative ceiling. | ddpharmatech.com |
| 2023-11-09 | Eccogene | China | AstraZeneca | ECC5004 / AZD5004 / elecoglipron | LICENSE | Ex-China exclusive; China co-development/co-commercialization | USD 185m | USD 2010m | Original company release says USD1.825bn milestones; do not round to USD1.8bn when calculating total. | www.prnewswire.com |
| 2024 | Sciwind Biosciences | China | Verdiva Bio | XW004/VRB-101; oral amylin VRB-103; injectable amylin VRB-102 | PORTFOLIO_LICENSE | Ex-Greater China/South Korea | — | — | Licence acquired in 2024 per launch release, publicly announced Jan 2025. Exact signing month/day undisclosed. USD411m Series A financing is NOT upfront payment. | verdivabio.com |
| 2024-03 | D&D Pharmatech | South Korea | Metsera | DD14; MET-AMYo; DD15; expansion of prior oral portfolio | PORTFOLIO_EXPANSION | Global | — | USD 381.05m | Incremental ceiling calculated as cumulative USD803.55m minus prior USD422.5m. Includes multiple new agreements/amendments in March; not a single-asset amount and not USD803.55m additional. | ddpharmatech.com |
| 2024-05-02 | Sciwind Biosciences | China | HK inno.N | Ecnoglutide / XW003 | LICENSE | South Korea | — | — | May 2 first announcement; May 7 joint release same agreement. Upfront and milestones payable, amounts undisclosed. | www.inno-n.com |
| 2024-05-15 | Hengrui Pharmaceuticals | China | Hercules CM NewCo / Kailera | HRS9531; HRS-7535; HRS-4729 | PORTFOLIO_LICENSE | Ex-mainland China/Hong Kong/Macau/Taiwan | USD 100m | USD 6035m | USD100m signing cash + USD10m tech transfer; future clinical/regulatory USD200m plus sales USD5725m. Total is component sum, excludes equity. 19.9% NewCo ownership not treated as cash. | www.sec.gov |
| 2024-12-18 | Hansoh Pharma | China | Merck/MSD | HS-10535 / MK-4082 | LICENSE | Global; conditional China commercialization option for Hansoh | USD 112m | USD 2012m | Development USD115m + regulatory USD315m + sales USD1470m = USD1900m milestones per 2024 10-K. Phase 1 threshold applies to assets table, not transaction table. | www.merck.com |
| 2025-03-24 | United Bio-Technology / United Laboratories | China | Novo Nordisk | UBT251 | LICENSE | Ex-mainland China/Hong Kong/Macau/Taiwan | USD 200m | USD 2000m | Royalties excluded. | www.novonordisk.com |
| 2025-06-02 | Hansoh Pharma | China | Regeneron | HS-20094 | LICENSE | Ex-mainland China/Hong Kong/Macau | USD 80m | USD 2010m | Taiwan is not listed in the excluded territory wording; do not expand retained territory to Greater China. | newsroom.regeneron.com |
| 2025-11-25 | Gan & Lee | China | Productos Cientificos / CARNOT Laboratorios | Bofanglutide / GZR18 | LICENSE | Latin America incl. Mexico/Brazil/Colombia | — | — | Company release dated Nov 26 with Nov 25 dateline; no numeric contract economics. | www.ganlee.com |
| 2025-12-29 | Gan & Lee | China | Lupin | Bofanglutide / GZR18 | LICENSE | India | — | — | Licence/supply/distribution; no disclosed numeric economics. | www.lupin.com |
| 2026-01-30 | CSPC Pharmaceutical | China | AstraZeneca | SYH2082 + three preclinical programs; four research programs; LiquidGel platform | PORTFOLIO_LICENSE | Ex-mainland China/Hong Kong/Macau/Taiwan; eight programs | USD 1200m | USD 18500m | USD3.5bn development/regulatory + USD13.8bn sales milestones. Broad metabolic portfolio; not a single-asset upfront. | www1.hkexnews.hk |
| 2026-04-08 | Gan & Lee | China | JW Pharmaceutical | Bofanglutide / GZR18 | LICENSE | South Korea | USD 5m | USD 81.1m | Issuer disclosure mirror; total USD81.1m includes upfront USD5m; milestones USD76.1m computed residual. Manufacturer release separately confirms same partnership. | cdn.financialreports.eu |
| 2026-09-03 | Gan & Lee | China | Menarini | Bofanglutide / GZR18 | LICENSE | 39 European countries/territories | EUR 62m | EUR 726m | EUR62m upfront; EUR664m milestones; EUR726m total confirmed by original Menarini release. No self-conversion to USD. Date follows original Menarini announcement; no inference of an earlier signing day. | www.menarini.com |
| 2026-09-29 | Hengrui Pharmaceuticals | China | Novo Nordisk | HRS-1596 | LICENSE | Ex-mainland China/Hong Kong/Macau/Taiwan | USD 300m | USD 2600m | Milestones USD2300m = USD2600m inclusive total minus USD300m upfront; early asset not added to clinical asset count. | www.novonordisk.com |
常見問題
收錄多少項亞洲 GLP-1 與肥胖藥計畫？
截至 2026 年 11 月 1 日，共 26 項計畫、18 個原創公司組別：中國 19 項、韓國 6 項、日本 1 項。本資料包未收錄台灣原創計畫。
哪項資產的階段最高？
Chugai Pharmaceutical 的 orforglipron 已核准。已核准是表內最高階段，共 6 項資產達到此階段；各資產核准的適應症與地區不同。
所有計畫都只作用於 GLP-1 嗎？
表內涵蓋 GLP-1 受體促效劑、雙重及多受體計畫，包含胜肽與小分子格式，各資產均列出機制與格式。
表內階段專指肥胖適應症嗎？
階段採來源中各適應症的最高進度；適應症欄分別列出糖尿病、肥胖或其他用途。糖尿病資產已核准，不等於肥胖用途也已核准。
列出多少筆亞洲對外授權事件？
共 15 筆對外授權與組合擴充事件。首付與潛在總額分開，各幣別不換匯，股權投資不列入首付款。